Fulgent Genetics, Inc. (FLGT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Fulgent Genetics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Fulgent Genetics, Inc. (FLGT) has returned -39.47% so far this year and -5.92% over the past 12 months.

Based on dividend-adjusted daily data since Sep 29, 2016, FLGT's average daily return is +0.14%, while the average monthly return is +2.28%. At this rate, your investment would double in approximately 2.6 years.

Historically, 44% of months were positive and 56% were negative. The best month was Jan 2021 with a return of +112.1%, while the worst month was Feb 2026 at -41.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, FLGT closed higher 48% of trading days. The best single day was Nov 5, 2019 with a return of +38.4%, while the worst single day was Feb 27, 2026 at -38.1%.

Fulgent Genetics, Inc. has an annualized alpha of 22.67%, beta of 1.06, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since September 30, 2016.

• This stock participated in 104.73% of S&P 500 Index downside but only 79.12% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

FLGT ranks 36 for risk / return — below 36% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Fulgent Genetics, Inc. (FLGT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Fulgent Genetics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Fulgent Genetics, Inc. was 92.50%, occurring on Mar 3, 2026. The portfolio has not yet recovered.

The current Fulgent Genetics, Inc. drawdown is 91.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Fulgent Genetics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Fulgent Genetics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.